Elizabeth Volz, MD
Advanced Heart Failure and Transplant Cardiology · Chapel Hill, NCNPI 1306012091
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (36.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Cvrx, Inc. accounts for 61.7% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $8,449, more than ten times the $458 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NC, where the typical reported total is $18,861.
Across 133 payments — averaging $133.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$11K
- Abbott$5K
- Ancora Heart, Inc.$476
- Abiomed$206
- Novartis$171
- Atricure, Inc.$152
- plus $320 from 8 others
Across 4 payments — averaging $10,343 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26K
- Novartis$15K
What the payments were for
- Consulting fees$5,40030%
- Travel & lodging$5,97134%
- Food & beverage$6,39436%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 43 | $10,962 |
| Abbott | 72 | $5,492 |
| Ancora Heart, Inc. | 2 | $476 |
| Abiomed | 2 | $206 |
| Novartis | 3 | $171 |
| Atricure, Inc. | 1 | $152 |
| Medtronic | 1 | $125 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $55 |
| AstraZeneca | 3 | $51 |
| Boehringer Ingelheim | 1 | $23 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Endotronix, Inc. | 1 | $18 |
| GSK | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$9,877
- CARDIOMEMS$1,670
- CardioMEMS HF System$1,532
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,147
- AccuCinch$388
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$152
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$152
- ATRICLIP LAA EXCLUSION SYSTEM$152
- ENTRESTO$125
- HeartWare HVAD$125
- Impella$113
How this compares
$17,779 in reported general payments places this provider in the 45th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 342 | $313,939 |
| JardianceEmpagliflozin | 198 | $198,649 |
| FarxigaDapagliflozin Propanediol | 62 | $57,373 |
| EliquisApixaban | 21 | $24,170 |
| Torsemide | 228 | $8,680 |
| Metoprolol Succinate | 444 | $7,645 |
| Warfarin Sodium | 140 | $3,247 |
| Spironolactone | 398 | $2,858 |
| Eplerenone | 13 | $1,371 |
| Potassium Chloride | 70 | $1,367 |
| Carvedilol | 160 | $1,206 |
| Hydralazine Hcl | 45 | $1,154 |
| Bumetanide | 16 | $962 |
| Losartan Potassium | 94 | $816 |
| Amiodarone Hcl | 27 | $638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $171 | $313,939342 claims |
| Boehringer IngelheimJardiance | $23 | $198,649198 claims |
| AstraZenecaFarxiga | $51 | $57,37362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Chapel Hill
- Jason KatzChapel Hill$44K
- William MostertzChapel Hill$3K
- Patricia ChangChapel Hill$697
- Brian JensenChapel Hill$55
- Daniel BensimhonGreensboro$2.1M
- Stephen GreeneDurham$582K
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Hassan AlhosainiWinston Salem$195K
- Vinay ThohanAsheville$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.